EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates

Samantha Powers, Shibi Likhite, Kamal K Gadalla, Carlos J Miranda, Amy J Huffenberger, Cassandra Dennys, Kevin D Foust, Pablo Morales, Christopher R Pierson, Federica Rinaldi, Stephanie Perry, Brad Bolon und 4 weitere

Molecular Therapy · 2023-09 · 31 (9) · 2767-2782

DOI: 10.1016/j.ymthe.2023.07.013 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Molecular Therapy, 2023-09. Verfasst von Samantha Powers und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, USA; Neuroscience Graduate Program, T…. Hauptthemen laut MEDLINE: Rett Syndrome. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rett Syndrome Research Trust, University of Edinburgh.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The AAV9 gene therapy vector presented in this study is safe in mice and non-human primates and highly efficacious without causing overexpression toxicity, a major challenge for clinical translation of Rett syndrome gene therapy vectors to date. Our team designed a new truncated methyl-CpG-binding protein 2 (MECP2) promoter allowing widespread expression of MECP2 in mice and non-human primates after a single injection into the cerebrospinal fluid without causing overexpression symptoms up to 18 months after injection. Additionally, this new vector is highly efficacious at lower doses compared with previous constructs as demonstrated in extensive efficacy studies performed by two independent laboratories in two different Rett syndrome mouse models carrying either a knockout or one of the most frequent human mutations of Mecp2. Overall, data from this multicenter study highlight the efficacy and safety of this gene therapy construct, making it a promising candidate for first-in-human studies to treat Rett syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rett SyndromeHumansMiceAnimalsPrimatesGenetic TherapyMutation

Stichwörter der Autor:innen

P546Rett syndromeadeno-associated virus serotype 9, scAAV9gene therapymethyl-CpG binding protein 2, MECP2

Autor:innen und Institutionen

  • Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, USA; Neuroscience Graduate Program, The Ohio State University, Columbus, OH 43210, USA. Electronic address:…
  • Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, USA.
  • Simons Initiative for the Developing Brain, Centre for Discovery Brain Sciences, University of Edinburgh, EH8 9XD Edinburgh, UK.
  • Neuroscience Graduate Program, The Ohio State University, Columbus, OH 43210, USA.
  • The Mannheimer Foundation Inc, Homestead, FL 33034, USA.
  • The Department of Pathology & Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH 43205, USA; Department of Pathology and the Department of Biomedical Education & Anatomy, The Ohio State University, Columb…

Förderung

  • Rett Syndrome Research Trust
  • University of Edinburgh

Zitieren

APA

Powers, S., Likhite, S., Gadalla, K. K., Miranda, C. J., Huffenberger, A. J., Dennys, C., Foust, K. D., Morales, P., Pierson, C. R., Rinaldi, F., Perry, S., Bolon, B., Wein, N., Cobb, S., Kaspar, B. K., & Meyer, K. C. (2023). Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates. Molecular Therapy, 31(9), 2767-2782. https://doi.org/10.1016/j.ymthe.2023.07.013

Vancouver

Powers S, Likhite S, Gadalla KK, Miranda CJ, Huffenberger AJ, Dennys C, et al. Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates. Molecular Therapy. 2023;31(9):2767-2782. doi:10.1016/j.ymthe.2023.07.013

BibTeX
@article{Powers2023,
  author = {Powers, Samantha and Likhite, Shibi and Gadalla, Kamal K and Miranda, Carlos J and Huffenberger, Amy J and Dennys, Cassandra and Foust, Kevin D and Morales, Pablo and Pierson, Christopher R and Rinaldi, Federica and Perry, Stephanie and Bolon, Brad and Wein, Nicolas and Cobb, Stuart and Kaspar, Brian K and Meyer, Kathrin C},
  title = {Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates},
  journal = {Molecular Therapy},
  year = {2023},
  volume = {31},
  number = {9},
  pages = {2767--2782},
  doi = {10.1016/j.ymthe.2023.07.013}
}
Kostenlos starten →